SCHOTT Pharma stock (DE000A3ENQ51): Pharmaceutical packaging specialist with global reach

SCHOTT Pharma maintains its position as a key supplier of primary packaging for injectable drugs, including glass syringes, vials, and cartridges. The company, spun off from SCHOTT AG in 2023, focuses on high-quality products for biologics and vaccines. Its solutions are used by major pharma players globally, with production sites in Europe, North America, and Asia.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

SCHOTT Pharma: core business model

SCHOTT Pharma develops and manufactures pharmaceutical primary packaging, specializing in glass and polymer products for parenteral drug delivery. Its portfolio includes ready-to-use syringes, vials, ampoules, and cartridges designed for biologics, vaccines, and insulin. The company emphasizes innovation in break systems and coatings to enhance drug stability and ease of use. Production follows strict GMP standards across multiple sites.

Listed on the Frankfurt Stock Exchange since its IPO in October 2023, SCHOTT Pharma targets the growing demand for injectable drugs driven by chronic diseases and biologics expansion. The business model relies on long-term supply contracts with pharma giants, ensuring recurring revenue. R&D investments focus on sustainable packaging and automation to meet regulatory and environmental demands.

Main revenue and product drivers for SCHOTT Pharma

Revenue is primarily generated from drug packaging for biologics (over 50% of sales), followed by classic injectables and insulin. Key products like SCHOTT topPAC polymer syringes and SCHOTT adapro cartridges support high-value therapies. In fiscal 2024, the company reported sales of around €800 million, with growth in North America contributing significantly, according to its annual report as of March 2025.

Geographic diversification includes 40% Europe, 30% Americas, and 30% Asia-Pacific. Strategic expansions, such as the new US facility in Wilson, North Carolina, bolster capacity for biologics packaging, aligning with US market growth in mRNA vaccines and monoclonal antibodies.

Industry trends and competitive position

The pharmaceutical packaging market is projected to grow at 7-9% CAGR through 2030, fueled by biologics and self-injection devices. SCHOTT Pharma competes with Gerresheimer, West Pharmaceutical, and Stevanda, differentiating through its adapro prefillable syringe platform and pharma-grade polymer expertise. Its vertical integration from glass tubing to finished products provides cost efficiencies.

For US investors, SCHOTT Pharma offers exposure to the $50 billion+ US injectables market via its American operations and contracts with domestic biotech firms. The company's focus on GLP-1 therapies for diabetes and obesity aligns with booming US demand.

Why SCHOTT Pharma matters for US investors

SCHOTT Pharma's US presence, including a manufacturing site in North Carolina, positions it to capture growth from American pharma innovation. With US biotech funding rebounding and demand for specialized packaging rising, the stock provides indirect play on key healthcare trends without direct drug development risks. Shares trade over-the-counter in the US, enhancing accessibility.

Conclusion

SCHOTT Pharma stands as a reliable player in pharmaceutical packaging, benefiting from secular trends in biologics and injectables. Its global footprint and innovation pipeline support long-term relevance, particularly in high-growth US markets. Investors track capacity expansions and contract wins for future performance indicators.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.